Company Interview / US expansion allows ResMed to breathe easy on tariffs

ResMed (ASX:RMD) reports an 8% revenue hike to $1.3 billion, fuelled by demand for sleep devices and masks, and robust growth in residential care software. CEO Mick Farrell highlights improved gross margins and operational income.

Mick states ResMed (ASX:RMD) received tariff exemptions from the Trump administration, aiding exports from Sydney and Singapore. He mentions a solid balance sheet and upcoming expansions in the US, specifically for R&D and manufacturing.

Mick sees growth potential in the US market, particularly with GLP-1 users showing increased adherence to CPAP therapy. He mentions ResMed's strategic approach using technology and direct marketing to expand their customer base.